Ocumension Therapeutics

1477.HK

HKSEHealthcareBiotechnology

فتح في GoAI

أحدث البيانات المتاحة

‏5.21 HK$

−‏0.085 HK$ · ‎-1.61‎%‎

24 أغسطس، 3:59 م HKT

تستخدم الأوقات اليومية المنطقة الزمنية HKT. قد تتأخر بيانات السوق.

ملف الشركة

موقع الشركة

Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeutic solutions for individuals with various eye conditions. Its extensive product offerings target treatments for disorders such as blepharitis, infectious and allergic conjunctivitis, dry eye syndrome, cataracts, glaucoma, ocular hypertension, post-surgical inflammation, uveitis, retinitis pigmentosa, age-related macular degeneration, corneal graft rejection, myopia, and optic neuritis. By December 31, 2021, Ocumension Therapeutics boasted a pipeline of 20 drug assets. The company, founded in 2017, maintains its headquarters in Suzhou, China.

صناعة: Biotechnology
قطاع: Healthcare
المقر الرئيسي: CN
المدير التنفيذي: Ye Liu
المدرجة منذ ذلك الحين: 10 يوليو 2020
موظفين: 552